3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

The article recommends three high-yield dividend stocks for the second half of 2026: Novo Nordisk (3.5% yield) is positioned to regain market share in GLP-1 drugs with its superior pill formulation despite pricing pressures; Realty Income (5% yield) offers stable, conservative dividend growth through its diversified net lease REIT portfolio; and Enterprise Products Partners (5.9% yield) provides reliable energy infrastructure income through a toll-taker model insulated from oil price volatility.

07/11/2026, 9:15 AM • The Motley Fool

Novo Nordisk’s $50 Price Frames a Value Versus Value Trap Debate

Novo Nordisk trades near $50, down 75% from its June 2024 peak of $142.44, caught between a turnaround narrative and structural decline thesis. The stock has recovered from $35 lows on the back of a blockbuster oral Wegovy pill launch and Q1 earnings beat, but faces persistent headwinds from Eli Lilly's competitive dominance in GLP-1 drugs, pipeline setbacks with CagriSema, US pricing pressure, and patent erosion. At 11.8x forward earnings with a 3.6% dividend yield, the market is divided on whether the stock represents genuine value or a value trap.

07/10/2026, 2:10 PM • Investing

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.

07/08/2026, 5:21 PM • The Motley Fool

Is It Too Late to Buy Eli Lilly?

Eli Lilly stock has surged 400% over five years, driven by dominance in the GLP-1 weight loss drug market with products like Mounjaro and Zepbound generating over $12 billion in recent quarterly sales. Despite the stock's significant gains and current $1,200+ price, analysts suggest it remains reasonably valued with strong growth prospects from its oral drug Foundayo and promising pipeline candidate retatrutide, making it still worth considering for investors.

07/08/2026, 2:10 PM • The Motley Fool

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026

Eli Lilly's stock is predicted to reach $1,400 by end of 2026 (15% gain from July levels), driven by expanded drug access rather than efficacy. The company's new oral obesity drug Foundayo, combined with $27 billion in manufacturing expansion, direct pharmacy distribution, and Medicare pricing deals, positions it to reach patients that injectable competitors cannot. However, competition from Novo Nordisk, premium valuation, and execution risks remain concerns.

07/08/2026, 8:30 AM • The Motley Fool

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

While Eli Lilly and Novo Nordisk are leaders in the GLP-1 market, Becton, Dickinson and Abbott Laboratories offer better indirect exposure to the GLP-1 boom. Becton, Dickinson supplies prefillable syringes with soaring demand and is a Dividend King, while Abbott's continuous glucose monitoring devices see increased adoption alongside GLP-1 medicines.

07/07/2026, 5:30 PM • The Motley Fool

Hims & Hers Pullback Could Create a Better Entry Into GLP-1 Demand

Hims & Hers (HIMS) has surged 45% in the past month and 160% year-to-date, but technical indicators suggest a correction is due. However, a major catalyst looms: employers are planning to drop GLP-1 drug coverage in 2027, which should drive patients to direct-to-consumer telehealth providers like Hims & Hers. The stock's RSI is overbought at 70.86, and Wall Street remains bearish with only 4 of 16 analysts rating it a Buy, suggesting a pullback could present a better entry point for long-term investors.

07/07/2026, 11:37 AM • Investing

Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.

Eli Lilly is positioned to benefit from the booming obesity drug market, projected to grow from $15 billion in 2024 to $150 billion by 2035. With new products like the pill-form Foundayo and next-generation Retatrutide in development, analysts expect 15% annual earnings growth over the next decade. At current valuations, a $1,000 investment could potentially grow to approximately $2,580 in 10 years, suggesting the stock still offers attractive long-term returns despite its 160% surge over the past three years.

07/07/2026, 8:10 AM • The Motley Fool

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Eli Lilly and Teva Pharmaceutical represent two different pharmaceutical strategies: Eli Lilly dominates the high-growth GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, posting 44% revenue growth and trading at a 33x forward P/E. Teva operates in generics and biosimilars with lower valuations (16.4x forward P/E) but faces declining sales projections for 2026 and significant debt challenges. The article recommends Eli Lilly as the better buy despite premium valuation due to its continued GLP-1 growth momentum.

07/06/2026, 1:09 PM • The Motley Fool

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?

Viking Therapeutics' lead drug candidate VK2735, a dual GLP-1/GIP agonist, shows promise in the competitive weight-loss market with potential for rapid weight loss via injectable form followed by oral maintenance. However, the company faces significant risks including safety concerns from phase 2 trials, long development timelines (phase 3 results not expected until 2027-2028), and likely acquisition by a larger pharmaceutical company if successful.

07/06/2026, 7:15 AM • The Motley Fool

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

Viking Therapeutics' obesity drug candidate VK2735 could potentially grow a $1,000 investment to $2,500-$3,400 by 2030 under favorable conditions, but faces significant competition from established players Eli Lilly and Novo Nordisk. The company will likely need to dilute shares through fundraising, and the drug must capture at least 1% market share to justify current valuations. Clinical trial failure could reduce investments by 60-80%.

07/05/2026, 1:05 AM • The Motley Fool

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying

Viking Therapeutics, a $4.3B biotech company, is developing VK2735, a weight loss drug candidate in late-stage trials. Bulls cite the massive $100B obesity drug market opportunity, potential acquisition interest, and positive historical stock reactions to data releases. Bears highlight competition from pharma giants Eli Lilly and Novo Nordisk, pipeline risk, and the stock's 40% year-over-year gain. The analyst believes the bull case outweighs the bear case, suggesting Viking could reach $50 if upcoming data proves positive.

07/04/2026, 5:10 AM • The Motley Fool

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Johnson & Johnson is deliberately avoiding the competitive GLP-1 weight-loss drug market, instead focusing on oncology and its medical device business where it has established strengths. This diversified strategy, combined with a lower valuation (P/E of 29x vs. Eli Lilly's 40x+) and higher dividend yield (2.1% vs. 0.6%), may make J&J a more attractive long-term investment despite missing out on the hot obesity drug trend.

07/03/2026, 9:15 PM • The Motley Fool

Here's Why Viking Therapeutics Stock Surged Higher in June

Viking Therapeutics stock rose 19.2% in June driven by optimism over its weight-loss drug pipeline, particularly VK2735, a GLP-1/GIP agonist showing steeper weight loss rates than competitors. The company also initiated a Phase 1 trial for VK3019, a new class of weight-loss drug with a different mechanism. Investors await Phase 3 trial results expected in 2027-2028 and Phase 1 maintenance trial results in Q3 2026.

07/03/2026, 9:25 AM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool